Skip to content

ABT-450/r/ABT-267

DRUG9 trials

Sponsors

AbbVie

Conditions

Absolute BioavailabilityChronic Hepatitis CChronic Hepatitis C InfectionChronic Hepatitis C Virus (HCV)Chronic Hepatitis C Virus (HCV) Infection Genotype 1Compensated Cirrhosis and Non-cirrhoticsHealthy VolunteerHepatitis C Virus

Phase 1

Phase 2

Phase 3

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection
CompletedNCT02023112
AbbVieHepatitis C Virus
Start: 2014-01-31End: 2015-09-30Updated: 2021-07-30
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
CompletedNCT02023099
AbbVieChronic Hepatitis C Infection
Start: 2013-12-31End: 2015-10-31Updated: 2018-06-06
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
CompletedNCT02167945
AbbVieChronic Hepatitis C Virus (HCV) Infection Genotype 1
Start: 2014-06-12End: 2021-05-13Updated: 2022-07-19
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
CompletedNCT02219490
AbbVieChronic Hepatitis C Virus (HCV) Infection Genotype 1
Start: 2014-10-30End: 2021-05-13Updated: 2023-04-07
ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis
CompletedNCT02517528
AbbVieChronic Hepatitis C Virus (HCV)
Start: 2015-07-20End: 2017-03-16Updated: 2018-10-09

Related Papers